No Data
Huadong Pharmaceutical: Report for the first quarter of 2025
Express News | Huadong Medicine Says Q1 Net Profit up 6.1% Y/Y
Huadong Medicine Co., Ltd Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Huadong Medicine (SZSE:000963) Could Easily Take On More Debt
Research Reports on Mining丨Sinolink: Maintain Huadong Medicine "Buy" rating, performance growth trend is stable.
Sinolink's Research Reports indicate that Huadong Medicine (000963.SZ) is expected to achieve a net income of 3.512 billion yuan in 2024, a year-on-year increase of 23.72%; in the fourth quarter, the net income is projected to be 0.95 billion yuan, with a year-on-year growth of 46.16%. The pharmaceutical industry and micro-sectors are experiencing rapid growth, while the commercial and medical aesthetics sectors remain overall stable. The wholly-owned subsidiary in the domestic medical aesthetics sector, Xinkeli Medical Aesthetics, achieved revenue of 1.139 billion yuan during the reporting period, an increase of 8.32% year-on-year, with continuous improvement in profitability. The innovation R&D layout is continually being enriched, and clinical progress is being actively promoted. In the endocrine field, the company’s independently developed oral small molecules.
Huadong Pharmaceutical: 2024 Annual Report
Fewer Investors Than Expected Jumping On Huadong Medicine Co., Ltd (SZSE:000963)
